A 58-year-old man with a history of hypertension presents with palpitations and is found to have atrial fibrillation with a rapid ventricular response (HR 140/min). An ECG shows the characteristic action potential phases of a ventricular myocyte. The structure marked **C** in the diagram represents the phase responsible for excitation-contraction coupling in cardiac muscle. Which of the following drugs would be most appropriate for rate control in this patient, given its mechanism of action on this phase?